Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.

@article{Okeefe2013SafetyAE,
  title={Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.},
  author={Stephen J D O'keefe and Palle B Jeppesen and Richard Gilroy and Marek Pertkiewicz and Johane P Allard and Bernard Messing},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2013},
  volume={11 7},
  pages={815-23.e1-3}
}
BACKGROUND & AIMS Although home parenteral nutrition (PN) can save the lives of patients with massive bowel loss that results in short-bowel syndrome and intestinal failure, quality of life is impaired by PN and its complications. We examined the 12-month tolerability and efficacy of teduglutide to reduce PN dependency. METHODS Patients who received teduglutide (0.05 or 0.10 mg/kg/d) for 24 weeks in a randomized controlled trial were eligible for a 28-week double-blind extension study; 52… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…